普雷加巴林治疗肺癌导致的慢性咳:随机,双盲,安慰剂对照试验
Vanita Noronha1, Nandini Menon1, Vijay M Patil2
1Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India.
British journal of cancer
|November 26, 2024
概括
在肺癌患者中,普雷加巴林并没有显著降低咳的严重程度. 系统性癌症疗法是这种人群中咳的最有效治疗方法.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 咳是肺癌患者常见和令人痛苦的症状,需要有效的治疗方法.
- 神经调节剂,如普雷加巴林,正在研究其潜在的中央止效应.
研究的目的:
- 评估pregabalin在降低肺癌患者咳严重性的疗效.
- 为了在随机,双盲,受控试验环境中将普雷加巴林与安慰剂进行比较.
主要方法:
- 一项随机,双盲,安慰剂控制的研究涉及166名患有局部晚期/转移性肺癌和持续咳的患者.
- 患者接受了普雷加巴林 (每天300毫克) 或安慰剂9周.
- 主要终点是咳严重程度的变化,用视觉模拟尺度 (VAS) 评分进行测量.
主要成果:
- 普雷加巴林和安慰剂组均显示VAS得分从基线到第9周的下降.
- 在pregabalin和安慰剂手臂之间没有观察到咳严重性减少的统计学上显著差异 (P=0.877).
- 系统性癌症导向疗法在两组患者中的很高比例中被启动,两组之间没有显著的差异.
结论:
- 在患有肺癌的患者中,普雷加巴林在显著减少咳方面无效.
- 系统性癌症导向疗法似乎是最有效的方法来管理咳在这个患者群体.
相关概念视频
Chronic Obstructive Pulmonary Disease-V: Nursing Management
3.6K
Nursing management of Chronic Obstructive Pulmonary Disease (COPD) is crucial for providing thorough care and support to patients. Nurses play an integral role in this process through detailed assessment, careful planning, targeted interventions, and ongoing evaluation. Here's an overview of the critical steps in nursing management for COPD.
Assessment
Assessment
3.6K
Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
202
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
202
Antiepileptic Drugs: Potassium Channel Activators
146
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
146
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
232
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
232
COPD: Management Using Bronchodilators and Corticosteroids
179
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
179


